Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
August 15, 2022 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
May 12, 2022 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
May 11, 2022 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
March 31, 2022 16:01 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
January 10, 2022 07:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis
December 17, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial Treatment was safe and well-tolerated, with no...
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results
November 15, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results
August 05, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...